特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者效果研究*

doi:10.3969/j.issn.1672-5069.2022.03.023

摘要/Abstract

摘要： 目的观察采用腹水浓缩回输术联合特利加压素治疗肝硬化并发顽固性腹水(RA)患者的效果。方法 2016年5月～2021年5月我院诊治的62例肝硬化并发RA患者被随机分为对照组31例和观察组31例,分别给予腹水浓缩回输术或在此治疗的基础上应用特利加压素治疗7 d。使用全自动生化分析仪检测血尿素氮(BUN)和血肌酐(sCr),使用超声诊断仪测量门静脉内径(DPV)、脾静脉内径(DSV)、门静脉血流速度(VPV)和脾静脉血流速度(VSV],应用WHO生命质量测定简式量表(WHOQOL-BREF)评估生命质量。结果在治疗7d后,观察组腹围为(85.5±4.5)cm,腹水深度为(35.2±3.4)mm,均显著小于对照组【分别(88.4±4.3)cm和(47.2±5.1)mm,P<0.05】,24 h尿量为(1530.8±30.2)ml,显著多于对照组【(1248.6±28.4)ml,P<0.05】;观察组血清BUN和sCr水平分别为(6.6±1.5)μmol/L和(104.2±8.7)μmol/L,显著低于对照组【分别为(9.8±2.4)μmol/L和(133.5±11.2)μmol/L,P<0.05】,而两组肝功能指标比较,无显著性差异(P>0.05);观察组VPV为(25.7±5.4)cm/s,显著高于对照组【(22.5±4.6)cm/s,P<0.05】,而两组DPV、DSV和VSV比较,差异无统计学意义(P>0.05);观察组WHOQOL-BREF评分总分为(65.6±12.3)分,显著高于对照组【(56.1±9.8)分,P<0.05】。结论采用腹水浓缩回输术联合特利加压素治疗肝硬化并发RA患者近期疗效较好,可显著改善肾功能,促进腹水消退,继而改善生命质量。

关键词: 肝硬化, 顽固性腹水, 特利加压素, 腹水浓缩回输术, 治疗

Abstract: Objective The aim of this study was to observe the very short-term efficacy of concentrated ascites reinfusion (CAR) and terlipressin combination therapy in the treatment of patients with liver cirrhosis (LC) and refractory ascites (RA). Methods 62 patients with LC and RA were admitted to our hospital between May 2016 and May 2021, and were randomly divided into control (n=31) and observation group (n=31). The patients in the control group were treated with CAR, and those in the observation group were treated with CAR and terlipressin combination. The regimen lasted for 7 days in the two groups. The blood urea nitrogen (BUN) and serum creatinine (sCr) levels were detected by an automatic biochemical analyzer. The diameter of portal vein (DPV), the diameter of splenic vein (DSV), the velocity of portal vein (VPV) and the velocity of splenic vein (VSV) were measured with ultrasonography. The WHO quality of life (WHOQOL-BREF) questionnaire was applied to evaluate the quality of life (QOL). The abdominal circumference, depth of ascites, 24 hour urine volume and the incidence of adverse reactions were recorded. Results At the end of 7 day treatment, the abdominal circumference was (85.5±4.5)cm, and the depth of ascites was (35.2±3.4)mm, both significantly smaller than [(88.4±4.3)cm and (47.2±5.1)mm, respectively, P<0.05], while the 24 hour urine volume was (1530.8±30.2)ml, significantly greater than [(1248.6±28.4)ml, P<0.05] in the control; the BUN and sCr levels were (6.6±1.5)μmol/L and(104.2±8.7)μmol/L, both significantly lower than [(9.8±2.4)μmol/L and (133.5±11.2)μmol/L, respectively, P<0.05] in the control, while there was no significant difference respect to liver function tests in the two groups (P>0.05); the VPV was (25.7±5.4)cm/s, significantly higher than [(22.5±4.6)cm/s, P<0.05] in the control, while there were no significant differences respect to DPV, DSV and VSV in the two groups(P>0.05); the total WHOQOL-BREF score was (65.6±12.3), significantly higher than [(56.1±9.8), P<0.05] in the control. Conclusion The CAR and terlipressin combination therapy in the treatment of patients with LC and complicated RA is relatively efficacious, from the point of view of the very short-time, which could improve kidney functions and promote ascites subsided, thereby improve the quality of life.

Key words: Liver cirrhosis, Refractory ascites, Concentrated ascites reinfusion, Terlipressin, Therapy

詹惠珍, 杜雅钦, 王松姣. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 395-398.

Zhan Huizhen, Du Yaqin, Wang Songjiao. Seven-day observation of concentrated ascites reinfusion and terlipressin combination therapy in the treatment of patients with liver cirrhosis and refractory ascites[J]. Journal of Practical Hepatology, 2022, 25(3): 395-398.

参考文献

[1] Kamimura K, Sakamaki A, Kamimura H, et al. Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. World J Gastroenterol, 2019,25(15):1817-1827.
[2] Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, et al. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol, 2020, 26(39):5919-5943.
[3] Tellez L, Ibanez-Samaniego L, Perez Del Villar C, et al. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol, 2020, 73(6):1404-1414.
[4] Stockhoff L, Schultalbers M, Tergast TL, et al. Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. PLoS One, 2020, 15(6):e0235199.
[5] Shimizu S, Ohira M, Nakano R, et al. Management of refractory ascites for liver transplant candidates: A novel cell-free and concentrated ascites reinfusion therapy. Transplant Proc, 2019, 51(8):2740-2744.
[6] Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology, 2020, 71(2):600-610.
[7] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21(1):21-31.
[8] 盛义岭, 王晨宇, 彭朋,等. 吸气肌训练对老年女性心脏自主神经功能及生活质量的影响.中华物理医学与康复杂志,2021,43(10):910-919.
[9] Neong SF, Adebayo D, Wong F, et al. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol, 2019, 13(4):293-305.
[10] Stirnimann G, Berg T, Spahr L, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther, 2017, 46(10):981-991.
[11] Stepanova M, Nader F, Bureau C, et al. Patients with refractory ascites treated with alfapump© system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. Qual Life Res, 2018, 27(6):1513-1520.
[12] 黄鹏, 沈秀微, 吴淑娟,等. 腹水浓缩回输联合头孢哌酮钠舒巴坦钠腹腔注射治疗肝硬化并发腹水感染的临床效果.中华医院感染学杂志,2019,29(7):984-988.
[13] Zhang J, Rossle M, Zhou X, et al. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. Curr Med Res Opin, 2019, 35(5):859-868.
[14] Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med, 2019, 45(6):844-855.
[15] 陈照林, 董静, 宋海燕,等. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究.实用肝脏病杂志,2020,23(4):556-559.
[16] 张惠勇, 吴秀欣, 徐成润,等. 特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析.实用肝脏病杂志,2020,23(2):244-247.
[17] Sharma P, Moore K, Ganger D, et al. Role of terlipressin and albumin for hepatorenal syndrome in liver transplantation. Liver Transpl, 2020, 26(10):1328-1336.
[18] Xu B, Liu J, Liu S, et al. Clinical effect of single covered stent and double covered stent on TIPS in the treatment of hemorrhage due to rupture of esophageal and gastric varices in cirrhosis and its influence on immune function. Exp Ther Med, 2019,18(6):4259-4264.
[19] Ortoleva J, Shapeton A, Vanneman M, et al. Vasoplegia during cardiopulmonary bypass: Current literature and rescue therapy options. J Cardiothorac Vasc Anesth, 2020, 34(10):2766-2775.
[20] Czuczejko J, Mila-Kierzenkowska C, Szewczyk-Golec K. Plasma α-glutathione S-transferase evaluation in patients with acute and chronic liver injury. Can J Gastroenterol Hepatol, 2019, 2019:5850787.

特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者效果研究^*

Seven-day observation of concentrated ascites reinfusion and terlipressin combination therapy in the treatment of patients with liver cirrhosis and refractory ascites

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[2]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[3]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.
[4]	柴晓哲, 朱霞峰, 骆成林, 王少峰. 泛基因型与特异基因型DAAs方案精准治疗基因1b型慢性丙型肝炎患者疗效对比分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 355-358.
[5]	胡春霞, 杨娇楠, 张丰晓, 胡敬华. 格卡瑞韦/哌仑他韦治疗基因1b型慢性丙型肝炎患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 359-362.
[6]	陈业京, 陆清平, 顾少颖. 异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 371-374.
[7]	杨海华, 周聪, 沈国强, 尤晓红, 孟玲. 134例替加环素致药物性肝损伤老年患者临床特征回顾性分析[J]. 实用肝脏病杂志, 2022, 25(3): 375-378.
[8]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[9]	沈扬林, 谭可平, 游忠岚, 陈婵, 陆晖, 甘琼萍, 覃国琦, 陆鹏. 血浆置换序贯双重血浆分子吸附系统治疗慢加急性乙型肝炎肝衰竭患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 387-390.
[10]	孙亚男, 曾庆环, 刘远志, 张世斌, 李鹏, 武永乐, 丁惠国. 伴有中/重度食管静脉曲张的慢加急性肝衰竭患者预后危险因素分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 391-394.
[11]	郭慧雯, 张峰, 肖江强, 张玮, 张明, 邹晓平, 诸葛宇征. 球囊导管闭塞下逆行性静脉栓塞术治疗胃静脉曲张破裂出血患者疗效分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 407-410.
[12]	邱云, 杨玫, 薛红红. TACE联合超声引导下微波消融治疗特殊部位原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 419-422.
[13]	马虎成, 任昊桢, 汤宁, 王帅, 张玉衡, 施晓雷. 机器人与开腹手术治疗肝内胆管细胞癌患者近期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 423-426.
[14]	江攀, 张惠林, 刘海, 苏娟. 超声引导下穿刺硬化治疗肝肾囊肿患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 439-442.
[15]	孙皆齐, 姜绍文, 汪铮. 应用艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎初治和经治患者效果对比研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 195-198.